GlassScriptPhysician profile
Edward D Ziga
NPI 1548478126
$568.91
in general payments reported to CMS, 2019-2025
10 companies · $113 in 2025
The $113 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.11 · 2021: $28.22 · 2022: $19.24 · 2023: $148 · 2024: $208 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.91 |
| Travel and Lodging | $122.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genetix Biotherapeutics INC | $269.43 | 2024-2025 | Lyfgenia |
| National Marrow Donor Program | $122.43 | 2023 | |
| Amgen INC. | $42.13 | 2019-2021 | |
| Csl Behring | $31.17 | 2025 | Idelvion, Afstyla |
| Adaptive Biotechnologies Corporation | $25.14 | 2023 | Clonoseq |
| Shire North American Group INC | $22.89 | 2019 | |
| Rare Disease Therapeutics, INC. | $20.17 | 2025 | Xromi |
| Duchesnay USA Incorporated | $19.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ziga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.